Loading
Leads the German Breast Group, whose GeparX trials defined neoadjuvant chemotherapy and immunotherapy in breast cancer.
Sibylle Loibl is Chief Executive Officer and Chair of the German Breast Group (GBG). Her specialisms are breast cancer, neoadjuvant trials and pathological complete response. She led GeparSixto, GeparNuevo and GeparDouze, trials of carboplatin and immunotherapy before surgery in triple-negative and HER2-positive breast cancer that shaped today's standards. Her Annals of Oncology paper on GeparNuevo reported a randomised phase II study of durvalumab added to anthracycline and taxane-based neoadjuvant therapy in early triple-negative breast cancer. Her German Breast Group profile and PubMed listing are linked.
| Title | Journal | Year |
|---|---|---|
| A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer (GeparNuevo) | Annals of Oncology | 2019 |
| ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer | New England Journal of Medicine | 2021 |
| KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment | New England Journal of Medicine | 2019 |
| OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer | New England Journal of Medicine | 2021 |
Platinum and immunotherapy are now consensus for early triple-negative disease; the open votes have moved to who can safely receive less.
This is the European standard the UK page for triple-negative breast cancer is compared against; NICE guidance covers the same ground with a narrower set of funded drugs.
St Gallen is where de-escalation questions in triple-negative disease (who needs the full KEYNOTE-522 regimen, who can skip adjuvant pembrolizumab) are first put to a vote; the 2023 panel framed intensity and duration as the central problem.
Sacituzumab govitecan is a standard second-line or later treatment for metastatic triple-negative breast cancer, roughly doubling survival compared with the chemotherapies it was tested against. Patients should expect neutropenia and diarrhoea, which are manageable with growth factor support and loperamide. Trials are now testing it earlier, in first-line combinations with pembrolizumab and after surgery for residual disease.
The trial-grade HER2-low share for TNBC is about a third, and the survival difference hints that HER2-zero triple-negative disease is the more aggressive group.
Everyone with HER2-negative early breast cancer that meets high-risk criteria should be offered germline BRCA testing, because a positive result now changes treatment: a year of olaparib after chemotherapy reduces relapse and death. It does not apply to low-risk tumours, HER2-positive disease, or somatic-only BRCA mutations.
HER2-positive breast cancer is now routinely treated before surgery so that the pathology result can guide what comes after: patients with no residual cancer continue trastuzumab (with or without pertuzumab), while those with residual disease switch to T-DM1. This model of using the tumour's response as a test has since been copied in triple-negative and other cancers.
The survival evidence behind platinum in early triple-negative disease, and the first large demonstration that most triple-negative tumours are DNA-repair deficient whether or not BRCA is mutated, which is why HRD scores have not become a platinum selection test.
Shares Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy, Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials, Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial, Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Shares Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto, German Breast Group (GBG), KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem.
Shares Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial, Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto, BrighTNess, German Breast Group (GBG).
Shares BrighTNess, KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment, OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem.
Shares BrighTNess, Pathologic complete response (pCR), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Carboplatin.
Shares Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023, Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC).
Shares KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment, ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, Pathologic complete response (pCR), Triple-negative breast cancer (TNBC).
Shares KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment, OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer, Triple-negative breast cancer (TNBC).